Suppr超能文献

与含前列腺素E的海绵体内注射药物相关的疼痛与前列腺癌根治术后勃起功能恢复不良有关。

Pain associated with prostaglandin E-containing intracavernosal injection medication is associated with poor erectile function recovery after radical prostatectomy.

作者信息

West Michael, Cordon Billy H, Ortega Yanira, Narus Joseph, Mulhall John P

机构信息

Sexual and Reproductive Medicine Program, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

出版信息

Andrology. 2024 Oct 26. doi: 10.1111/andr.13784.

Abstract

BACKGROUND

Intracavernosal injection therapy is often used as second-line therapy for erectile dysfunction associated with radical prostatectomy when therapy with phosphodiesterase-5 inhibitors has failed, but prostaglandin E1-containing vasoactive agents are associated with penile pain in some men.

OBJECTIVES

To define the incidence of pain with prostaglandin E1-containing intracavernosal injection mixtures for erectile dysfunction associated with radical prostatectomy when therapy with phosphodiesterase-5 inhibitors has failed, and whether pain was a predictor of erectile function recovery.

MATERIALS AND METHODS

Men who underwent radical prostatectomy and were commenced on intracavernosal injection within 12 months of radical prostatectomy were included. A pain visual analog scale (0-10) was used to assess the degree of pain. Erectile function recovery was defined as the International Index of Erectile Function domain score ≥24 using phosphodiesterase-5 inhibitors at 24 months.

RESULTS

The study included 566 patients, mean age was 58 ± 14 (42-74) years. Duration post-radical prostatectomy at intracavernosal injection training was 3.5 ± 3.5 m. Nerve sparing status: bilateral 76%, unilateral 13%, and non-nerve sparing 11%. Incidence of pain with intracavernosal injection per nerve sparing status: bilateral 10% of patients, unilateral 32%, non-nerve sparing 92% (p < 0.001). Median visual analog scale in those experiencing pain: bilateral 4 (interquartile range 3, 5), unilateral 5.5 (interquartile range 3, 6), non-nerve sparing 7 (interquartile range 3, 9) (p < 0.001). Phosphodiesterase-5 inhibitors success at 24 months (no pain vs. pain): bilateral 70% vs. 40% (p < 0.001), unilateral 50% vs. 28% (p < 0.001), non-nerve sparing 10% vs. 0% (p < 0.001). On multivariate analysis, predictors of failure to respond to phosphodiesterase-5 inhibitors at 24 months post-radical prostatectomy included baseline erectile function, increasing age, incomplete nerve-sparing surgery, and presence of pain.

DISCUSSION

The presence of penile pain with intracavernosal injection is associated with poorer erectile function recovery post-radical prostatectomy.

CONCLUSIONS

Incidence of pain is high in men with non-nerve sparing radical prostatectomy; older patient age, poorer nerve sparing, poor baseline erectile function, and the presence of penile pain with prostaglandin E1-containing intracavernosal injection medication, were predictive of poor erectile function recovery using phosphodiesterase-5 inhibitors at 24 months.

摘要

背景

当磷酸二酯酶-5抑制剂治疗失败时,海绵体内注射疗法常被用作根治性前列腺切除术后勃起功能障碍的二线治疗方法,但含前列腺素E1的血管活性药物在部分男性中会引起阴茎疼痛。

目的

确定在磷酸二酯酶-5抑制剂治疗失败后,用于根治性前列腺切除术后勃起功能障碍的含前列腺素E1的海绵体内注射混合剂引起疼痛的发生率,以及疼痛是否为勃起功能恢复的预测指标。

材料与方法

纳入在根治性前列腺切除术后12个月内开始接受海绵体内注射治疗的男性患者。采用疼痛视觉模拟量表(0-10分)评估疼痛程度。勃起功能恢复定义为在24个月时使用磷酸二酯酶-5抑制剂时国际勃起功能指数领域评分≥24分。

结果

该研究共纳入566例患者,平均年龄为58±14(42-74)岁。根治性前列腺切除术后至海绵体内注射训练的时间为3.5±3.5个月。神经保留情况:双侧76%,单侧13%,非神经保留11%。不同神经保留情况下海绵体内注射疼痛的发生率:双侧患者中10%,单侧32%,非神经保留92%(p<0.001)。疼痛患者的视觉模拟量表中位数:双侧为4(四分位间距3,5),单侧为5.5(四分位间距3,6),非神经保留为7(四分位间距3,9)(p<0.001)。24个月时磷酸二酯酶-5抑制剂治疗成功情况(无疼痛与有疼痛):双侧为70%对40%(p<0.001),单侧为50%对28%(p<0.001),非神经保留为10%对0%(p<0.001)。多因素分析显示,根治性前列腺切除术后24个月对磷酸二酯酶-5抑制剂无反应的预测因素包括基线勃起功能、年龄增加、神经保留手术不完整以及存在疼痛。

讨论

海绵体内注射引起阴茎疼痛与根治性前列腺切除术后较差的勃起功能恢复相关。

结论

非神经保留根治性前列腺切除术男性患者疼痛发生率较高;年龄较大、神经保留较差、基线勃起功能较差以及含前列腺素E1的海绵体内注射药物引起阴茎疼痛,是24个月时使用磷酸二酯酶-5抑制剂勃起功能恢复较差的预测因素。

相似文献

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验